Acadia Pharmaceuticals

Latest news

• Neuren Phase 2 trial shows significant improvements in Pitt Hopkins syndrome
  28 May 2024
• FDA Approves Daybue (trofinetide) for the Treatment of Rett Syndrome
  13 March 2023
• Acadia Pharmaceuticals Announces Trofinetide New Drug Application for the Treatment of Rett Syndrome has been Accepted for Filing and Review by U.S. FDA
  12 September 2022
• Acadia Pharmaceuticals Submits New Drug Application to the U.S. FDA for Trofinetide for the Treatment of Rett Syndrome
  18 July 2022
• Acadia Pharmaceuticals Announces Positive Top-line Results from the Pivotal Phase 3 Lavender Trial of Trofinetide in Rett Syndrome
  6 December 2021
• FDA Issues Statement Reaffirming the Positive Benefit-Risk Profile of Nuplazid (pimavanserin) for Patients with Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis
  20 September 2018
• Acadia Pharmaceuticals Announces FDA Approval of New Dosing Formulation and Strength for Nuplazid (pimavanserin)
  29 June 2018
• FDA Approves Nuplazid (pimavanserin) for Parkinson’s Disease Psychosis
  29 April 2016
• FDA Advisory Committee Votes 12 to 2 That Benefits of Nuplazid (Pimavanserin) for the Treatment of Psychosis Associated with Parkinson’s Disease Outweigh the Risks
  29 March 2016
• Acadia Pharmaceuticals Announces FDA Priority Review of Nuplazid (Pimavanserin) NDA for Parkinson’s Disease Psychosis
  2 November 2015

Drugs Associated with Acadia Pharmaceuticals, Inc.

Acadia Pharmaceuticals, Inc. manufactures, markets and/or distributes more than 2 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.